BCL2 and asthma: Notably, treating patients with non‐eosinophilic inflammatory pathways is clinically challenging, though ongoing research into new therapies like Bcl‐2 inhibitors and agents targeting neutrophil chemoattractants shows some promise but RCTs in pediatric populations with asthma are needed to confirm their efficacy.24